Biopharmaceutical In-House Manufacturing Rates Decline
New data shows companies shifting strategy as industry-wide supply chain constraints and regulatory requirements intensify.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Do you believe drug supply chain issues will lead to higher prescription costs for your household?
A 2025 BioPlan Associates survey reports that 17.4% of companies now keep cell and gene therapy manufacturing in-house, down from 30% in the prior year. This shift reflects broader adjustments as the biopharmaceutical industry contends with supply chain constraints and federal traceability requirements.
Why it matters
Trade policy uncertainty is driving companies toward risk-adjusted supply chain models. This transition significantly impacts the scalability of modern therapeutics, which increasingly require complex, temperature-controlled logistics.
Lead times for fill/finish manufacturing currently range from 18 to 30 months. While more than $5 billion has been invested in this capacity since 2022, manufacturers face significant hurdles meeting the Drug Supply Chain Security Act requirements for package-level traceability.
The players
BioPlan Associates
A market research firm specializing in the biopharmaceutical manufacturing industry.
The details
Companies are increasingly adopting modular manufacturing, a process where standardized facility designs are reused to accelerate construction and deployment. For newer, temperature-sensitive therapeutic modalities, producers are deploying advanced cold chain management. This involves ultra-low temperature storage, validated transport routes, and real-time sensors paired with predictive analytics to ensure product integrity during distribution.
Timeline
2022 marked the beginning of a $5 billion investment push in fill/finish capacity.
April 2025 saw the publication of the BioPlan Associates manufacturing capacity survey.
The Tech Race
Regulatory compliance with the Drug Supply Chain Security Act is forcing a transformation in how therapies move from labs to patients. The industry is currently shifting away from concentrated in-house models to prioritize resilient, traceable distribution networks.
The 18-to-30-month lead time for specialized fill/finish services suggests that drug availability will remain sensitive to logistical bottlenecks. Companies that successfully implement modular, tech-enabled cold chains may see more reliable production timelines for high-precision therapies.
The takeaway
The industry's move toward flexible, risk-adjusted supply chains reflects a long-term shift to accommodate sensitive biological modalities. Stakeholders should monitor future capacity survey updates to see if the recent $5 billion investment effectively compresses standard 18-month lead times.
Further reading
For broader trends in the industry, explore our Biotech section.
Source note: This article includes information reported by BioPharm International.
Live Poll
Do you believe drug supply chain issues will lead to higher prescription costs for your household?
